EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study

Carlos Jiménez-Vicente, Ares Guardia-Torrelles, Amanda Isabel Pérez-Valencia, Alexandra Martínez-Roca, Sandra Castaño-Diez, Francesca Guijarro, Albert Cortés-Bullich, Beatriz Merchán, Ana Triguero, Isabel Hernández, Helena Brillembourg, Daniel Munárriz and 4 more

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05923-5 ↗

At a glance

Journal article in Annals of Hematology, 2024. Written by Carlos Jiménez-Vicente and 15 co-authors. Institution: Hematology Department, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. Major MEDLINE topics: Sulfonamides, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Cited 5 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: Universitat de Barcelona.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) and its use in different AML settings will be expanded in the following years, the management of the adverse events (AEs) lacks of harmonized algorithms during treatment of these patients. We have studied the incidence of relevant AEs of 43 patients who achieved a response to VenHMA and its management. Median overall survival of our cohort was 19 months. No patients discontinued treatment due to AEs after C3D1, Regarding severe AEs, high rates of grade 4 neutropenia (97.6%) and grade 4 thrombocytopenia (65.1%) were observed. Severe infectious AEs rate was 16%. Due to severe myelotoxicity, most patients required a progressive dose reduction of both venetoclax and hypomethylating agents during follow-up, being 87.8% at C6D1. Transfusional dependence rate was 91% and G-CSF was prescribed to 86% of the patients. Finally, there was not a significant difference in hemoglobin, platelets and absolute neutrophil count after achieving complete response comparing paired samples during follow-up, although cytopenia rate was high during initial follow-up. We conclude that dose reduction of VenHMA after achieving a response in patients diagnosed with AML is required in most patients and essential to avoid prolonged cytopenia-related adverse events and a rapid and standardized method on how to perform it might decrease the AEs rate.

Subjects

MeSH terms (MEDLINE)

SulfonamidesLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedAdultAged, 80 and overThrombocytopeniaDecitabineAzacitidineFollow-Up StudiesRetrospective StudiesNeutropenia

Author keywords

AMLAdverseeventsCytopeniasManagementVenetoclax

Substances

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicDecitabineAzacitidine

Authors and institutions

  • Hematology Department, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
  • University of Barcelona, Barcelona, Spain.
  • Pathology Department. Hospital Clinic, Hemopathology Unit, Barcelona, Spain.
  • Hematology Department, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. jesteve@clinic.cat.
  • Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. jesteve@clinic.cat.

Funding

  • Universitat de Barcelona

Cite

APA

Jiménez-Vicente, C., Guardia-Torrelles, A., Pérez-Valencia, A. I., Martínez-Roca, A., Castaño-Diez, S., Guijarro, F., Cortés-Bullich, A., Merchán, B., Triguero, A., Hernández, I., Brillembourg, H., Munárriz, D., Zugasti, I., Fernández-Avilés, F., Diaz-Beyá, M., & Esteve, J. (2024). Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05923-5

Vancouver

Jiménez-Vicente C, Guardia-Torrelles A, Pérez-Valencia AI, Martínez-Roca A, Castaño-Diez S, Guijarro F, et al. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05923-5

BibTeX
@article{JimnezVicente2024,
  author = {Jiménez-Vicente, Carlos and Guardia-Torrelles, Ares and Pérez-Valencia, Amanda Isabel and Martínez-Roca, Alexandra and Castaño-Diez, Sandra and Guijarro, Francesca and Cortés-Bullich, Albert and Merchán, Beatriz and Triguero, Ana and Hernández, Isabel and Brillembourg, Helena and Munárriz, Daniel and Zugasti, Inés and Fernández-Avilés, Francesc and Diaz-Beyá, Marina and Esteve, Jordi},
  title = {Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05923-5}
}
Start for free →